WO2001028493A2 - Inhibiteurs a petite molecule de la necrose - Google Patents

Inhibiteurs a petite molecule de la necrose Download PDF

Info

Publication number
WO2001028493A2
WO2001028493A2 PCT/US2000/028475 US0028475W WO0128493A2 WO 2001028493 A2 WO2001028493 A2 WO 2001028493A2 US 0028475 W US0028475 W US 0028475W WO 0128493 A2 WO0128493 A2 WO 0128493A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
bond
hydrogen
compound
necrosis
Prior art date
Application number
PCT/US2000/028475
Other languages
English (en)
Other versions
WO2001028493A3 (fr
Inventor
Junying Yuan
Alexei Degterev
Timothy Mitchison
Original Assignee
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard College filed Critical President And Fellows Of Harvard College
Publication of WO2001028493A2 publication Critical patent/WO2001028493A2/fr
Publication of WO2001028493A3 publication Critical patent/WO2001028493A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/205—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
    • C07C43/2055—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring containing more than one ether bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C07C49/245—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C07C49/245—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings
    • C07C49/248—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the invention relates to methods and compounds used to decrease necrosis.
  • necrotic and/or necrotic pathways In many diseases, cell death is mediated through apoptotic and/or necrotic pathways. While much is known about the mechanisms of action that control apoptosis, control of necrosis is not as well understood. Understanding the mechanisms regulating both necrosis and apoptosis in cells is essential to being able to treat conditions, such as neurodegenerative diseases, stroke, coronary heart disease, kidney disease, and liver disease. A thorough understanding of necrotic and apoptotic cell death pathways is also crucial to treating AIDS and the conditions associated with AIDS, such as retinal necrosis. Research has shown that caspases play a central role in the induction of apoptosis.
  • Peptide based inhibitors of caspases such as zVAD-fmk are useful in preventing activation of the apoptotic cell death pathway in cells stimulated to undergo apoptosis by compounds such as TNF ⁇ .
  • zVAD-fmk cells treated with zVAD-fmk and these cell death stimuli still die through a caspase- independent form of necrosis.
  • Discovery of a compound which prevents caspase-independent cell death (necrosis) would provide a useful therapeutic for treating conditions in which necrosis occurs, and for preventing the onset of necrosis.
  • These compounds and methods may be particularly useful for treating ischemic brain and heart injuries and head traumas.
  • the present invention features methods and compounds for decreasing necrosis.
  • the compounds of the present invention may be used as therapeutics to decrease necrosis in a desired cell, such as a neuron. These compounds are characterized by their ability to decrease necrosis in response to modulation of intracellular signaling pathways, such as those activated by TNF ⁇ .
  • a desired cell such as a neuron.
  • These compounds are characterized by their ability to decrease necrosis in response to modulation of intracellular signaling pathways, such as those activated by TNF ⁇ .
  • intracellular signaling pathways such as those activated by TNF ⁇ .
  • the invention features a chemical compound in a pharmaceutically acceptable carrier, having the formula:
  • each R is independently selected from the group consisting of hydrogen, carboxy, methyl, hydroxyl, methoxyl, amino, and nitro;
  • R 2 is selected from the group consisting of hydrogen, alkyl, and acyl;
  • R 3 is selected from the group consisting of alkyl, acyl, halogen, hydrogen, or hydroxyl;
  • R 4 is selected from the group consisting of methyl, hydroxyl, carboxyl, and linear and branching alkyl groups;
  • acyl group of R ⁇ or R 3 is selected from the group consisting of:
  • R 2 is a hydrogen
  • R ⁇ is a not a hydrogen
  • R 3 is not a hydrogen
  • R 4 is not a methyl group
  • Y S
  • R 3 is a hydrogen
  • R is a not a hydrogen
  • R 2 is not a hydrogen
  • R 4 is not a methyl group
  • bond (a) is not a double bond
  • bonds (b) and (c) are not each single bonds.
  • R 4 is a methyl group
  • the invention features a compound in a pharmaceutically acceptable carrier, having the formula:
  • R ⁇ is selected from the group consisting of hydrogen and hydroxyl;
  • R 2 is selected from the group consisting of hydrogen, sulfate, nitro, and halide; and the bond (a) is either a single or double bond.
  • R t is a hydroxyl group
  • R 2 is a nitro group
  • the invention features a chemical compound in a pharmaceutically acceptable carrier, having the formula:
  • each R, and R 2 is independently selected from the group consisting of hydrogen, amino, halide, and hydroxyl; R 3 is selected from the group consisting of hydrogen and methyl; and the bond (a) is either a single or double bond.
  • each R is hydrogen; R 2 is fluorine; R 3 is a methyl group; and the bond (a) is a double bond.
  • R x is a hydrogen
  • R 2 is not fluorine; or R 3 is not a methyl group; or the bond (a) is not a double bond.
  • R 2 is a fluorine
  • R, is not hydrogen
  • R 3 is a not a methyl group
  • the bond (a) is not a double bond.
  • R, is not hydrogen, or R 2 is not fluorine; or the bond (a) is not a double bond.
  • the bond (a) is a double bond
  • the invention features a chemical compound in a pharmaceutically acceptable carrier, having the formula:
  • the invention features a method for decreasing necrosis, involving contacting a cell with a chemical compound having the formula:
  • each R is independently selected from the group consisting of hydrogen, carboxy, methyl, hydroxyl, methoxyl, amino, and nitro;
  • R 2 is selected from the group consisting of hydrogen, alkyl, and acyl;
  • R 3 is selected from the group consisting of alkyl, acyl, halogen, hydrogen, or hydroxyl;
  • R 4 is selected from the group consisting of methyl, hydroxyl, carboxyl, and linear and branching alkyl groups;
  • acyl group of R, or R 3 is selected from the group consisting of:
  • R 2 is a hydrogen
  • R is a not a hydrogen
  • R 3 is not a hydrogen
  • R 4 is not a methyl group
  • Y S
  • R 3 is a hydrogen
  • R is a not a hydrogen
  • R 2 is not a hydrogen
  • R 4 is not a methyl group
  • bond (a) is not a double bond
  • bonds (b) and (c) are not each single bonds.
  • R 4 is a methyl group
  • the invention features a method for decreasing necrosis, involving contacting a cell with a chemical compound having the formula:
  • R is selected from the group consisting of hydrogen and a hydroxyl;
  • R 2 is selected from the group consisting of hydrogen, sulfate, nitro, and halide; and the bond (a) is either a single or double bond.
  • the invention features a method for decreasing necrosis, involving contacting a cell with a chemical compound having the formula:
  • each R, and R 2 is independently selected from the group consisting of hydrogen, amino, halide, and hydroxyl; R 3 is selected from the group consisting of hydrogen and methyl; and the bond (a) is either a single or double bond.
  • each R is hydrogen; R 2 is fluorine; R 3 is a methyl group; and the bond (a) is a double bond.
  • R is a hydrogen
  • R 2 is not fluorine
  • R 3 is not a methyl group
  • the bond (a) is not a double bond.
  • R 2 is a fluorine
  • R is not hydrogen
  • R 3 is a not a methyl group
  • the bond (a) is not a double bond.
  • Ri is not hydrogen
  • R 2 is not fluorine; or R 3 is not a methyl group.
  • the cell is capable of undergoing necrosis in the presence of zVAD-fmk and TNF ⁇ .
  • the cell is capable of undergoing necrosis in the presence of zVAD-fmk and DMSO.
  • the cell is mammalian, such as a human or rodent cell.
  • the cell is a neuron.
  • the compound is in a pharmaceutically acceptable carrier.
  • the invention features a method for treating a condition in a subject, involving the steps of administering a chemical compound having the formula:
  • each R is independently selected from the group consisting of hydrogen, carboxy, methyl, hydroxyl, methoxyl, amino, and nitro;
  • R 2 is selected from the group consisting of hydrogen, alkyl, and acyl;
  • R 3 is selected from the group consisting of alkyl, acyl, halogen, hydrogen, or hydroxyl;
  • R 4 is selected from the group consisting of methyl, hydroxyl, carboxyl, and linear and branching alkyl groups;
  • acyl group of R ⁇ or R 3 is selected from the group consisting of:
  • R 2 is a hydrogen
  • R is a not a hydrogen
  • R 3 is not a hydrogen
  • R 4 is not a methyl group
  • Y S
  • R 3 is a hydrogen
  • R j is a not a hydrogen, or R 2 is not a hydrogen
  • R 4 is not a methyl group
  • bond (a) is not a double bond
  • bonds (b) and (c) are not each single bonds.
  • R 4 is a methyl group
  • the invention features a method for treating a condition in a subject, involving the steps of administering a chemical compound having the formula:
  • R, is a hydroxyl group, then each of X, and X 2 are not 0; or R 2 is a not a nitro group; or the bond (a) is not a double bond.
  • R 2 is a nitro group, then each of X !
  • the invention features a method for treating a condition in a subject, involving the steps of administering a chemical compound having the formula:
  • R 2 is independently selected from the group consisting of hydrogen, amino, halide, and hydroxyl; R 3 is selected from the group consisting of hydrogen and methyl; and the bond (a) is either a single or double bond.
  • each R j is hydrogen; R 2 is fluorine; R 3 is a methyl group; and the bond (a) is a double bond.
  • Rj is a hydrogen
  • R 2 is not fluorine; or R 3 is not a methyl group; or the bond (a) is not a double bond.
  • R 2 is a fluorine
  • R, is not hydrogen
  • R 3 is a not a methyl group
  • the bond (a) is not a double bond.
  • R 3 is a methyl group
  • R, is not hydrogen, or R 2 is not fluorine; or the bond (a) is not a double bond.
  • the bond (a) is a double bond
  • the invention features a method for treating a condition in a subject, involving the steps of administering a chemical compound having the formula:
  • the condition is a neurodegenerative disease.
  • the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Huntington's disease, cerebral ischemia, stroke, amyotropic lateral sclerosis, multiple sclerosis, Lewy body disease, Menkes, disease, Wilson disease, Creutzfeldt-Jakob disease, and Fahr disease.
  • the condition is ischemic brain or heart injury, or head trauma.
  • the subject is a mammal, such as a human or a rodent.
  • the invention features a method for identifying a compound that decreases necrosis, involving the steps of: providing a cell in which apoptosis is prevented; contacting the cell with a first compound that causes a cell to undergo necrosis; contacting the cell with a second compound; and measuring necrosis relative to a control cell, wherein a decrease in necrosis indicates that the second compound decreases necrosis.
  • apoptosis is prevented by contacting the cell with zVAD-fmk.
  • the first compound is TNF ⁇ or DMSO.
  • any of the R, X, or Y groups of the compounds of the invention, or of the compounds used in any method of the invention may be alkyl derivatives or contain alkyl linkers.
  • necrosis is meant reducing the number of cells which undergo necrosis relative to a control cell, receiving a cell death stimulus, such as TNF ⁇ /zNAD-fmk or DMSO/zVAD-fmk without a candidate small molecule inhibitor.
  • a cell death stimulus such as TNF ⁇ /zNAD-fmk or DMSO/zVAD-fmk without a candidate small molecule inhibitor.
  • necrosis is decreased 10% relative to a control. More preferably necrosis is decreased 50% relative to a control. Most preferably necrosis is decreased 90% relative to a control.
  • a decrease in necrosis is tested by determining the ATP level in a cell which has received a test compound, such as a compound from a chemical library, and comparing it to the ATP level in a control cell. Necrosis is decreased in a cell treated with a test compound in which the ATP level does not decrease as much as it does in the control cell.
  • test compound is meant a chemical, be it naturally-occurring or artificially-derived, that is surveyed for its ability to modulate the level of necrosis by employing one of the assay methods described herein.
  • Test compounds may include, for example, peptides, polypeptides, synthesized organic molecules, naturally occurring organic molecules, nucleic acid molecules, and components thereof.
  • cell death is meant the death of a cell by either apoptosis or necrosis.
  • necrosis caspase-independent cell death characterized by cellular ATP depletion.
  • the cell is depleted of ATP 10% relative to a control cell, receiving vehicle only (for example, DMSO). More preferably, the cell is depleted of ATP 50% relative to a control cell. Most preferably, the cell is depleted of ATP 90% relative to a control cell.
  • necrosis is tested by determining the ATP level in a cell which has received a compound, for example, zVAD-fmk, DMSO, or TNF ⁇ , and comparing it to the ATP level in a cell receiving vehicle only.
  • Necrosis occurs in a cell treated with a test compound in which the ATP level decreases relative to the control cell. Necrosis may be liquifactive, may affect adipose or hepatic tissue, and may be caseous or fibrinoid. A cell may undergo necrosis in response to ischemic cell injury or viral infection.
  • caspase-independent cell death cell death that occurs when apoptosis is prevented. Apoptosis may be prevented by contacting a cell with a caspase inhibitor such as zVAD-fmk at a concentration sufficient enough that the cell survives when stimulated to undergo apoptosis, for example, by treatment with an apoptosis-promoting drug or ionizing radiation.
  • a caspase inhibitor such as zVAD-fmk
  • apoptosis is meant cell death characterized by any of the following properties: nuclear condensation, DNA fragmentation, membrane blebbing, or cell shrinkage.
  • modulation of intracellular signaling pathways mediated by TNF ⁇ is meant a change in the communication between components of a cell in response to contacting the cell with TNF ⁇ .
  • the change may be in the way or duration in which proteins within the cell interact, or the way or duration in which proteins are altered, such as by phosphorylation or dephosphorylation, or in the way or duration in which proteins interact with DNA.
  • modulation of intracellular signaling pathways mediated by DMSO is meant a change in the communication between components of a cell in response to contacting the cell with DMSO.
  • the change may be in the way or duration in which proteins within the cell interact, or the way or duration in which proteins are altered, such as by phosphorylation or dephosphorylation, or in the way or duration in which proteins interact with DNA.
  • treating is meant to submit or subject an animal, cell, lysate or extract derived from a cell, or a molecule derived from a cell to a test compound that decreases necrosis.
  • condition is meant a state of being or feeling.
  • Conditions include, but are not limited to, neurodegenerative disease, stroke, liver disease, pancreatic disease, ischemic brain or heart injury or other ischemic injuries, head trauma, a necrotic ulceration, septic shock, coronary heart disease, gastrointestinal disease, tuberculosis, alteration of blood vessels, viral infection (e.g., HIV infection or AIDS), or conditions associated with HIV infection or AIDS.
  • neurodegenerative disease stroke, liver disease, pancreatic disease, ischemic brain or heart injury or other ischemic injuries, head trauma, a necrotic ulceration, septic shock, coronary heart disease, gastrointestinal disease, tuberculosis, alteration of blood vessels, viral infection (e.g., HIV infection or AIDS), or conditions associated with HIV infection or AIDS.
  • HIV infection e.g., HIV infection or AIDS
  • neurodegenerative disease is meant a disease characterized by neuronal cell death.
  • neurodegenerative diseases include, but are not limited to, Alzheimer's disease, Huntington's disease and related polyglutamine expansion diseases, cerebral ischemia, stroke, amyotropic lateral sclerosis, multiple sclerosis, Lewy body disease, Menkes disease, Wilson disease, Creutzfeldt-Jakob disease, and Fahr disease.
  • neuron is meant a cell of ectodermal embryonic origin derived from any part of the nervous system of an animal. Neurons express well- characterized neuron-specific markers which include neurofilament proteins, MAP2, and class III ⁇ -tubulin. Included as neurons are, for example, hippocampal, cortical, midbrain dopaminergic, motor, sensory, sympathetic, septal cholinergic, and cerebellar neurons.
  • a "dosage sufficient to decrease necrosis” is meant an amount of a chemical compound or small molecule which when administered to a subject will decrease necrosis. Preferably necrosis is decreased in the subject 10% relative to an untreated subject. More preferably necrosis is decreased in the subject 50% relative to an untreated subject.
  • necrosis is decreased in the subject 90% relative to an untreated subject.
  • measuring necrosis is meant determining if a cell is dying through necrosis, in the presence of a compound, compared to a cell which is not in the presence of the compound (control cell).
  • Necrosis can be measured by determining cellular ATP levels, wherein a cell that is undergoing necrosis has a decreased level of cellular ATP compared to a control cell.
  • Necrosis may also be measured by staining with a vital dye, for example, trypan blue, wherein a cell which is necrosing will be stained with the vital dye, and a cell which is not necrosing will not be stained with the dye.
  • a “derivative” is meant a structural derivative having a chemical modification of the compound which does not reduce the ultimate level of necrosis, but which does enhance bioavailability, solubility, or stability in vivo or ex vivo or which reduces the toxicity or dosage required. Such modifications are known to those skilled in the field of medicinal chemistry.
  • the present invention provides a number of advantages. For example, the methods described herein allow for a decrease in cell death occurring through a necrosis pathway. The invention also provides compounds and methods for treating diseases in which necrosis occurs.
  • These compounds and methods can be used to treat conditions such as a neurodegenerative disease, stroke, liver disease, pancreatic disease, ischemic heart or brain injury or other ischemic injuries, head trauma, septic shock, coronary heart disease, gastrointestinal disease, tuberculosis, alteration of blood vessels, viral infection, such as HIV or AIDS, or conditions associated with a viral infection such as HIV or AIDS.
  • conditions such as a neurodegenerative disease, stroke, liver disease, pancreatic disease, ischemic heart or brain injury or other ischemic injuries, head trauma, septic shock, coronary heart disease, gastrointestinal disease, tuberculosis, alteration of blood vessels, viral infection, such as HIV or AIDS, or conditions associated with a viral infection such as HIV or AIDS.
  • Fig. 1 is a schematic representation of the chemical structure of a molecule which may be used to decrease necrosis.
  • each R is independently selected from the group consisting of hydrogen, methyl, carboxy, hydroxyl, methoxyl, amino, and nitro;
  • R 2 is selected from the group consisting of hydrogen, alkyl, and acyl;
  • R 3 is selected from the group consisting of alkyl, acyl, halogen, hydrogen, or hydroxyl;
  • R 4 is selected from the group consisting of methyl, hydroxyl, carboxyl, and linear and branching alkyl groups;
  • Fig. 2 is a schematic representation of the chemical structure of chemical compound ID number 115807 from the ChemB ridge chemical compound library.
  • Fig. 3 is a schematic representation of the chemical structure of a molecule which may be used to decrease necrosis.
  • R is selected from the group consisting of hydrogen and a hydroxyl;
  • R 2 is selected from the group consisting of hydrogen, sulfate, nitro, and halide; and
  • the bond (a) is either a single or double bond.
  • Fig. 4 is a schematic representation of the chemical structure of chemical compound ID number 115681 from the ChemBridge chemical compound library.
  • Fig. 5 is a schematic representation of the chemical structure of a molecule which may be used to decrease necrosis.
  • each R t and R 2 is independently selected from the group consisting of hydrogen, amino, halide, and hydroxyl;
  • R 3 is selected from the group consisting of hydrogen and methyl; and
  • the bond (a) is either a single or double bond.
  • Fig. 6 is a schematic representation of the chemical structure of chemical compound ID number 210227 from the ChemB ridge chemical compound library.
  • Fig. 7 is a schematic representation of the chemical structure of a molecule which may be used to decrease necrosis.
  • each R is independently selected from the group consisting of H or CH 3 ;
  • the bond (a) is either a single or double bond;
  • the bond (b) is either a single or double bond;
  • Fig. 8 is a schematic representation of the chemical structure of chemical compound ID number 215686 from the ChemBridge chemical compound library.
  • Assays that measure cell necrosis may be used to facilitate the identification of molecules that decrease necrosis induced by stimuli, such as zVAD-fmk/TNF ⁇ .
  • zVAD-fmk is added to the culture media of cells at high density (for example, 5xl0 5 or 7.5xl0 5 cells/ml), which are capable of undergoing necrosis in response to zVAD-fmk/TNF ⁇ .
  • Candidate molecules for example, chemical compounds from the ChemBridge chemical library are added, in varying concentrations to the cells, and the cells are then exposed to TNF ⁇ .
  • necrosis of the treated cells is then measured, for example, by measuring the cellular ATP level of the cells exposed to zV AD- fmk/TNF ⁇ (Crouch et al. J. Immunol. Methods 160:81-8, 1993; Storer et al. Mutat. Res. 368:59-101, 1996; and Cree et al. Toxicol. In Vitro 11 :553-556, 1997).
  • the level of necrosis in the presence of the candidate molecule is compared to the level of necrosis in the absence of the candidate molecule, all other factors (e.g., cell type and culture conditions) being equal.
  • zVAD-fmk The importance of zVAD-fmk in the invention is to block cell death that may occur by apoptosis, so that cell death by necrosis can be fully unmasked.
  • a cell may be exposed to a candidate molecule that decreases necrosis at the same time it is exposed to either zVAD-fmk or TNF ⁇ .
  • a cell may be exposed to zVAD-fmk and TNF ⁇ first, and then to a candidate compound. The level of necrosis that occurs following each of these approaches is measured as described above.
  • candidate molecules on necrosis induced by cell death stimuli may also be measured by other methods, for example, vital dye staining, using dyes such as trypan blue or acridine orange/ethidium bromide.
  • Compounds that decrease necrosis may be purified or substantially purified, or may be one component of a mixture of compounds, such as a pool of chemical compounds.
  • the occurrence of necrosis is tested against progressively smaller subsets of the compound pool (e.g., produced by standard purification techniques such as HPLC or FPLC) until a single compound or minimal number of effective compounds is demonstrated to decrease necrosis.
  • a molecule that promotes a decrease in necrosis induced by zVAD-fmk/TNF ⁇ is considered particularly useful in the invention; such a molecule may be used, for example, as a therapeutic to decrease necrosis, in a patient with a condition in which necrosis occurs, such as a neurodegenerative disease.
  • Chemical compounds that are found, by the methods described above, to effectively decrease necrosis induced, for example, by zVAD- fmk/TNF ⁇ in an in vitro system may be tested further in animal models.
  • Particularly useful animal models include mouse and rat models of cell death, ischemic brain or heart injury or other ischemic injuries, head trauma, neurodegenerative diseases, coronary heart disease, and septic shock.
  • models include SOD or Huntington's disease gene transgenic mice, and other known models, such as those described by Li et al. (Hum. Mol. Genet. 8: 1227-12236, 1999), Levine et al. (Neurosci. Res. 58:515-532, 1999), Vukosavic et al. (J. Neurochem. 73:2460-2468, 1999), Gruney (J. Neurol. Sci. 152 suppl. 1.S67-73, 1997), Deshmukh et al. (Am. J.
  • the small molecules identified to decrease necrosis may be structurally modified and subsequently used to decrease necrosis, or to treat a subject with a condition in which necrosis occurs.
  • the chemical compounds that decrease necrosis may be modified by one of the above processes or various combinations of the above processes.
  • the methods used to generate structural derivatives of the small molecules that decrease necrosis are readily known to those skilled in the fields of organic and medicinal chemistry. Therapy
  • a compound identified as capable of decreasing necrosis, using any of the methods described herein, may be administered to patients or animals with a pharmaceutically-acceptable diluent, carrier, or excipient, in unit dosage form.
  • the chemical compounds for use in such therapies may be produced and isolated by any standard technique known to those in the field of medicinal chemistry.
  • Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer the identified compound to patients suffering from a disease in which necrosis occurs. Administration may begin before the patient is symptomatic.
  • the therapy may be administered either directly to the site of a predicted cell death event (for example, by injection) or systemically (for example, by any conventional administration technique).
  • Administration of the compound may also be parenteral, intravenous, intraarterial, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmalic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, by suppositories, or oral administration.
  • Therapeutic formulations may be in the form of liquid solutions or suspensions; for oral administration, formulations may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders, nasal drops, or aerosols.
  • the dosage of the therapeutic compounds in a pharmaceutically-acceptable formulation depends on a number of factors, including the size and health of the individual patient.
  • the dosage to deliver may be determined by one skilled in the art. Methods well known in the art for making formulations are found, for example, in "Remington: The Science and Practice of Pharmacy” ((19th ed.) ed. A.R. Gennaro AR., 1995, Mack Publishing Company, Easton, PA).
  • Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes.
  • Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds.
  • Other potentially useful parenteral delivery systems for compounds that decreases necrosis include ethylene- vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
  • Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.
  • the methods and compounds of the present invention may be used to treat a number of diseases, as described above. Such methods and compounds may be particularly useful in treating ischemic brain or heart injury or head trauma. These diseases would be excellent targets of such therapies, as necrosis occurs in them.
  • treatment with a compound identified according to the methods described above may be combined with more traditional therapies for a disease characterized by cell death, such as tacrine hydrochloride for the treatment of Alzheimer's disease, or interferon ⁇ -la for the treatment of multiple sclerosis.
  • more traditional therapies for a disease characterized by cell death such as tacrine hydrochloride for the treatment of Alzheimer's disease, or interferon ⁇ -la for the treatment of multiple sclerosis.
  • any of the above therapies may be administered before the occurrence of the disease phenotype.
  • a heart disease e.g., coronary heart disease or ischemic heart injury
  • degenerative disease e.g., a neurodegenerative disease, such as Alzheimer's disease or Huntington's disease
  • any of the above therapies may be administered before the occurrence of the disease phenotype.
  • compounds shown to decrease necrosis may be administered by any standard dosage and route of administration (as described above).
  • the methods of the instant invention may be used to decrease necrosis of a cell or to treat disorders described herein in any mammal, for example, humans, domestic pets, or livestock.
  • the cell lines U-937 and BALB/c 3T3 were assayed for the occurrence of necrosis in response to the combined treatment of zVAD-fmk, a caspase inhibitor, and TNF ⁇ , a cell death stimulator.
  • the cells (5xl0 5 cells/ml) were exposed to zVAD-fmk (100 ⁇ M) and human TNF ⁇ (40 ng/ml) for 72 hours.
  • Induction of necrosis was assayed by measuring the cellular ATP levels in response to TNF ⁇ (Crouch et al., supra, Storer et al. supra, and Cree et al. supra).
  • the U-937 cell line was used to screen a library of 16,000 small molecule chemical compounds for a compound's ability to decrease necrosis induced by exposure of the cell to zVAD-fmk and TNF ⁇ .
  • the library of chemical compounds used in this screen were from ChemB ridge (ChemBridge
  • U-937 cells (5xl0 5 or 7.5xl0 5 cells/ml) were first exposed to zVAD-fmk (100 ⁇ M). Thirty minutes later the same cells were exposed to a chemical compound from the library (5 mg/ml, dissolved in
  • TNF ⁇ (40 ng/ml) was added to the cell culture medium.
  • the cells were then incubated at 37 °C for 72 hours, and were then assayed for cellular ATP levels.
  • Compounds which did not prevent a decrease in cellular ATP levels were compounds which did not prevent necrosis in response to treatment of the cell with zVAD-fmk and TNF ⁇ .
  • the compounds identified from the first screen, above, to decrease necrosis induced by zVAD-fmk and TNF ⁇ were assayed for their potency.
  • Serial dilution of each chemical compound was performed and the compounds were administered to U-937 cells, as per the primary screen.
  • the concentrations of each compound were 70 ⁇ M, 23 ⁇ M, 8 ⁇ M, and 2.5 ⁇ M.
  • the level of necrosis occurring in response to zVAD-fmk, TNF ⁇ , and the various concentrations of chemical compounds was assayed as described above for the primary screen.
  • a cell expressing a dominant negative form of the protein Fas- associated death domain can also prevent a cell from undergoing necrosis in response to treatment with zVAD-fmk/TNF ⁇ - or zVAD- fmk/DMSO.
  • Jurkat cells were stably transfected with a FADD-FKBP fusion construct (Kawahara A. et al. J. Cell Biol. 143(5): 1353-60, 1998). Normally such cells undergo apoptosis when FADD is multimerized.
  • the stably transfected Jurkat cells (500,000 cells/ml) were treated with 100 nM of FKBP dimerizer (Arraid Pharmaceuticals; used to stimulate FADD multimerization) in the presence of 100 ⁇ M of zVAD-fmk (pre-treated for 1 hour) and compounds from the library identified to decrease necrosis (dissolved in DMSO to give a final DMSO concentration of 0.5 %; added 30 minutes after zVAD-fmk) for 48 hours. Cell viability was then assessed by measuring cellular ATP levels.
  • the small molecules provided protection from necrosis induced in the presence of zVAD-fmk, but not from apoptosis induced by FADD dimerization in the absence of zVAD-fmk.
  • FADD may be involved in mediating necrosis in response to zVAD-fmk/TNF ⁇ - or zVAD-fmk/DMSO. It is possible that the small molecules that decrease necrosis may function by interacting with FADD and disrupting FADD's normal function of promoting necrosis upon treatment of a cell with zVAD-fmk/TNF ⁇ - or zVAD-fmk/DMSO.
  • Example 5 Identification of Intracellular Targets of Small Molecules that Decrease Necrosis
  • Molecules within a cell that interact with the small molecule compounds that decrease necrosis can be identified using a number of different strategies. Each strategy involves detecting interactions between various proteins from a cell and a small molecule that decreases necrosis, identified according to the methods described above. To identify proteins that interact with a small molecule that decreases necrosis, the small molecule may be bound to a bead, using methods known to those skilled in the art. Each strategy should be carried out using proteins from cells which have been exposed to zVAD-fmk/TNF ⁇ - or zVAD-fmk/DMSO.
  • the signaling complex containing FADD may be immunoprecipitated, using standard techniques known to those skilled in the art. This complex may then be added to the beads containing the desired small molecule compound that decreases necrosis. Proteins that interact with the small molecule that decreases necrosis may be identified by Western blot detection of proteins contained in the complex, or other techniques known to those skilled in the field of molecular biology. Any detected binding interactions indicate that the target of the small molecule that decreases necrosis is present in the immunoprecipitated FADD complex.
  • a cell may be fractionated, and the various fractionated pools may be assayed for interaction with the chemical compound using standard molecular biology techniques.
  • a pool of proteins which interacts with the small molecule that decreases necrosis indicates that the pool contains a protein that is a target of the small molecule that decreases necrosis.
  • the target of the small molecule that decreases necrosis may be isolated using techniques known to those skilled in the art.
  • a third strategy involves small pool expression screening systems.
  • Targets of a small molecule that decreases necrosis can be identified from any cell in which the small molecule protects cells from necrosis triggered by zVAD-fmk/TNF ⁇ - or zVAD-fmk/DMSO.
  • This method for identifying targets of small molecules that decrease necrosis can be done, for example, according to the methods of Lustig et al. (Methods in Enzymology 283:83-99, 1997). In this method a cDNA library is made from a desired cell line, or any other desired source.
  • the cDNA library is then divided into pools of 100 clones, and the cDNAs are transcribed and translated to form proteins pools for the detection of interactions between a protein and a small molecule that decreases necrosis. Interactions between the small molecules that decrease necrosis and pools of library proteins can be detected using standard molecular biology techniques, for example, SDS-PAGE.
  • the following modifications of the small molecules that decrease necrosis may be made and evaluated for their efficacy in decreasing necrosis, for example, that induced by zVAD-fmk TNF ⁇ or zVAD-fmk/DMSO.
  • the chemical compound 115807 may be modified by the introduction of a hydroxyl, methyl, carboxy, methoxyl, amino or nitro group into the benzyl ring (for example, at any or all of the R, positions of Fig. 1). Double bonds may be introduced in the linker between indol and hydantoin moieties (for example, in Fig. 1, bonds (a), (b), or (c) may be double bonds, provided that not both bonds (a) and (b) are double bonds).
  • the thiourea moiety may be reduced or alkylated (for example, the moiety may be -SH or SR 5 , wherein R 5 is an alkyl group).
  • the indol amino group may be reduced, alkylated, or acylated (for example, in Fig. 1, R 2 may be CH3, CH 3 (CH 2 ) n , where n is between 1 and 4 and, HOOC-(CH 2 ) n , where n is between 1 and 4,
  • the hydantoin 3 -methyl group may be substituted with linear or branching alkyl groups of varying length, and with hydroxyl, methyl, or acyl functionalities (for example the following groups may be present at the R4 position of Fig. 1; CH 3 , CH 3 (CH 2 ) n where n is between 1 and 4, OH, or HOOC- (CH 2 ) n -, wherein n is between 1 and 4.
  • the linker CH 2 group between the indol and hydantoin moieties can be alkylated, acylated, halogenated, or hydroxylated (for example, in Fig. 1, R 4 may be CH 3 , CH 3 (CH 2 ) n , where n is between 1 and 4, HOOC-(CH 2 ) n , where n is between 1 and 4,
  • hydantoin ketone moiety may be reduced to a hydroxyl group or a hydrogen.
  • the chemical compound 210227 may be modified by the attachment of a halide, or hydroxyl or amino groups to either or both of the benzyl rings (for example, in the R ⁇ or R 2 positions of Fig. 5).
  • the chemical compound 215686 may be modified by reducing the two central aliphatic double bonds, together, or each one individually.
  • the ketone may also be reduced, or the methoxyl groups may be substituted with hydroxyl groups, each individually, or together.
  • the chemical compound 115681 may be modified in the following ways.
  • the aliphatic double bond or the aliphatic ketone may be may be reduced.
  • the nitro group may be substituted with a proton, halide, or sulfate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Cette invention concerne des méthodes permettant de réduire la nécrose ainsi que des méthodes de traitement pour un sujet atteint d'une pathologie entraînant une nécrose. L'invention porte également sur des composés chimiques utilisés pour réduire le phénomène de nécrose.
PCT/US2000/028475 1999-10-15 2000-10-13 Inhibiteurs a petite molecule de la necrose WO2001028493A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15966899P 1999-10-15 1999-10-15
US60/159,668 1999-10-15
US17474900P 2000-01-06 2000-01-06
US60/174,749 2000-01-06

Publications (2)

Publication Number Publication Date
WO2001028493A2 true WO2001028493A2 (fr) 2001-04-26
WO2001028493A3 WO2001028493A3 (fr) 2001-06-07

Family

ID=26856169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/028475 WO2001028493A2 (fr) 1999-10-15 2000-10-13 Inhibiteurs a petite molecule de la necrose

Country Status (1)

Country Link
WO (1) WO2001028493A2 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094409A1 (fr) * 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Inhibiteurs de ido et procedes d'utilisation de ceux-ci
WO2005028463A1 (fr) * 2003-09-17 2005-03-31 Sumitomo Chemical Company, Limited Compose cinnamoyle et utilisation associee
WO2005077344A3 (fr) * 2003-08-29 2006-03-16 Brigham & Womens Hospital Inhibiteurs de la necrose cellulaire
JP2006104063A (ja) * 2003-09-17 2006-04-20 Sumitomo Chemical Co Ltd シンナモイル化合物及びその用途
EP1968583A2 (fr) * 2005-12-20 2008-09-17 President And Fellows Of Harvard College Composes, essais et methodes de traitement
WO2013059791A3 (fr) * 2011-10-21 2013-07-11 Massachusetts Eye And Ear Infirmary Procédés et compositions pour la promotion de la régénération axonale et de la fonction nerveuse
US9492432B2 (en) 2010-04-23 2016-11-15 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
US9499521B2 (en) 2014-12-11 2016-11-22 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
US9586880B2 (en) 2008-12-23 2017-03-07 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
US9993517B2 (en) 2010-11-01 2018-06-12 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving retinal ganglion cells
KR20180088068A (ko) * 2017-01-26 2018-08-03 중앙대학교 산학협력단 네크로스타틴-1을 포함하는 정원줄기세포의 동결보존용 조성물 및 이를 이용한 정원줄기세포의 동결보존 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693643A (en) * 1991-09-16 1997-12-02 Merck & Co., Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693643A (en) * 1991-09-16 1997-12-02 Merck & Co., Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383613B2 (en) 2003-03-27 2013-02-26 Lankenau Institute For Medical Research Methods for the treatment of cancer
WO2004094409A1 (fr) * 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Inhibiteurs de ido et procedes d'utilisation de ceux-ci
EP1613308A1 (fr) * 2003-03-27 2006-01-11 Lankenau Institute for Medical Research Procedes de traitement du cancer
US8008281B2 (en) 2003-03-27 2011-08-30 Lankenau Institute For Medical Research Methods for the treatment of cancer
US8476454B2 (en) 2003-03-27 2013-07-02 Lankenau Institute For Medical Research IDO inhibitors and methods of use
US7714139B2 (en) 2003-03-27 2010-05-11 Lankenau Institute For Medcial Research IDO inhibitors and methods of use
EP1613308A4 (fr) * 2003-03-27 2008-02-20 Lankenau Inst Medical Res Procedes de traitement du cancer
US7491743B2 (en) 2003-08-29 2009-02-17 President And Fellows Of Harvard College Inhibitors of cellular necrosis
EP3081214A3 (fr) * 2003-08-29 2016-11-16 The Brigham And Women's Hospital, Inc. Inhibiteurs de nécrose cellulaire
US8741942B2 (en) 2003-08-29 2014-06-03 President And Fellows Of Harvard College Inhibitors of cellular necrosis
JP2007504171A (ja) * 2003-08-29 2007-03-01 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 細胞壊死インヒビター
JP2011157404A (ja) * 2003-08-29 2011-08-18 Brigham & Women's Hospital Inc 細胞壊死インヒビター
WO2005077344A3 (fr) * 2003-08-29 2006-03-16 Brigham & Womens Hospital Inhibiteurs de la necrose cellulaire
EP2384753A1 (fr) * 2003-08-29 2011-11-09 The Brigham and Women's Hospital, Inc. Inhibiteurs de nécrose cellulaire
AU2004315596B2 (en) * 2003-08-29 2011-11-24 President And Fellows Of Harvard College Inhibitors of cellular necrosis
US8143300B2 (en) 2003-08-29 2012-03-27 President And Fellows Of Harvard College Inhibitors of cellular necrosis
US7691883B2 (en) * 2003-09-17 2010-04-06 Sumitomo Chemical Company, Limited Cinnamoyl compound and use of the same
JP2006104063A (ja) * 2003-09-17 2006-04-20 Sumitomo Chemical Co Ltd シンナモイル化合物及びその用途
WO2005028463A1 (fr) * 2003-09-17 2005-03-31 Sumitomo Chemical Company, Limited Compose cinnamoyle et utilisation associee
US8324262B2 (en) 2005-12-20 2012-12-04 The Brigham And Women's Hospital, Inc. Tricyclic necrostatin compounds
EP1968583A2 (fr) * 2005-12-20 2008-09-17 President And Fellows Of Harvard College Composes, essais et methodes de traitement
EP1968583A4 (fr) * 2005-12-20 2010-09-15 Harvard College Composes, essais et methodes de traitement
JP2009521454A (ja) * 2005-12-20 2009-06-04 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ 化合物、スクリーニング、および処置方法
US9586880B2 (en) 2008-12-23 2017-03-07 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
US10149884B2 (en) 2010-04-23 2018-12-11 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
US9492432B2 (en) 2010-04-23 2016-11-15 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
US10639345B2 (en) 2010-04-23 2020-05-05 Massachusetts Eye And Ear Infirmary Compositions for preserving photoreceptor cells, retinal pigment epithelial cells, or visual function
US10617735B2 (en) 2010-11-01 2020-04-14 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving retinal ganglion cells
US9993517B2 (en) 2010-11-01 2018-06-12 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving retinal ganglion cells
US10799552B2 (en) 2011-10-21 2020-10-13 Massachusetts Eye And Ear Infirmary Methods for treating diabetic neurotherapy
US10022419B2 (en) 2011-10-21 2018-07-17 Massachusetts Eye And Ear Infirmary Methods for treating spinal cord injury
WO2013059791A3 (fr) * 2011-10-21 2013-07-11 Massachusetts Eye And Ear Infirmary Procédés et compositions pour la promotion de la régénération axonale et de la fonction nerveuse
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
US9944628B2 (en) 2014-12-11 2018-04-17 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
US10508102B2 (en) 2014-12-11 2019-12-17 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
US9499521B2 (en) 2014-12-11 2016-11-22 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
KR20180088068A (ko) * 2017-01-26 2018-08-03 중앙대학교 산학협력단 네크로스타틴-1을 포함하는 정원줄기세포의 동결보존용 조성물 및 이를 이용한 정원줄기세포의 동결보존 방법
KR102635317B1 (ko) 2017-01-26 2024-02-08 중앙대학교 산학협력단 네크로스타틴-1을 포함하는 정원줄기세포의 동결보존용 조성물 및 이를 이용한 정원줄기세포의 동결보존 방법

Also Published As

Publication number Publication date
WO2001028493A3 (fr) 2001-06-07

Similar Documents

Publication Publication Date Title
US6756394B1 (en) Small molecule inhibitors of necrosis
US10322135B2 (en) Pharmaceutical composition comprising indole compound
Lee et al. Simvastatin inhibits NF-κB signaling in intestinal epithelial cells and ameliorates acute murine colitis
EP1218368B1 (fr) COMPOSITIONS ET PROCEDES DE MODULATION DE L'APOPTOSE DANS DES CELLULES SUREXPRIMANT DES PROTEINES DE LA FAMILLE bcl-2
US7531320B2 (en) Modulation of β-catenin/TCF-activated transcription
WO2001028493A2 (fr) Inhibiteurs a petite molecule de la necrose
US20100209429A1 (en) Peptides and methods for the treatment of gliomas and other cancers
JP2010530736A (ja) タプシガルジンにより誘導される細胞死の阻害剤
JP2009506054A (ja) 疾患を処置するためのヘッジホッグ経路アンタゴニスト
CN113924295A (zh) 激酶抑制剂
Sinha et al. Mahanine inhibits growth and induces apoptosis in prostate cancer cells through the deactivation of Akt and activation of caspases
EP3017825A1 (fr) Inhibiteur de la voie de nécrose à dépendance RIPK1 et composition pharmaceutique le contenant
JP2006507227A (ja) カスパーゼ活性化剤およびアポトーシス誘導剤としてのガンボジック酸誘導体および類似体
Lule et al. Genetic inhibition of receptor interacting protein kinase-1 reduces cell death and improves functional outcome after intracerebral hemorrhage in mice
WO2002102301A2 (fr) Benzylidene-hydrazides d'acide indole-2-carboxylique substitues et analogues utilises comme activateurs de caspases et inducteurs d'apoptose, et leur utilisation
WO2003077832A2 (fr) Dexanabinol et analogues de dexanabinol regulant des genes associes a l'inflammation
US9688651B2 (en) Geranyl geranyl acetone analogs and uses thereof
US20050137251A1 (en) Dexanabinol and dexanabinol analogs regulate inflammation related genes
WO2021098715A1 (fr) Inhibiteur phénothiazine de la ferroptose, son procédé de préparation et son utilisation
US20050165053A1 (en) Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
CN105189469B (zh) 2-氨基-3,4-二氢喹唑啉衍生物及其作为组织蛋白酶d抑制剂的用途
WO2018237174A2 (fr) Modulateurs de régulateur de conductance transmembranaire de fibrose kystique pour le traitement d'une polykystose rénale autosomique dominante
JP2002527350A (ja) 発作を治療するのに有用なアミノ酸誘導体
KR20150083353A (ko) 경요도적 주입용 방광암 예방 또는 치료를 위한 약제학적 조성물
KR102181346B1 (ko) 허혈-재관류계 질환의 치료 화합물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP